CD274 and non-small cell lung carcinoma: In addition, a pooled analysis of three randomized trials (KEYNOTE-407, KEYNOTE-189, and KEYNOTE-021 cohort G) in patients with advanced/metastatic NSCLC and PD-L1 levels less than 1%.